Pertuzumab for the treatment of breast cancer: a safety review. [Review]

MedStar author(s):
Citation: Expert Opinion on Drug Safety. 15(6):853-63, 2016 JunPMID: 26982349Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] | *Antineoplastic Agents/tu [Therapeutic Use] | *Breast Neoplasms/dt [Drug Therapy] | Antibodies, Monoclonal, Humanized/ae [Adverse Effects] | Antineoplastic Agents/ae [Adverse Effects] | Breast Neoplasms/pa [Pathology] | Disease-Free Survival | Female | Humans | Quality of Life | Receptor, ErbB-2/me [Metabolism] | Survival RateYear: 2016ISSN:
  • 1474-0338
Name of journal: Expert opinion on drug safetyAbstract: AREAS COVERED: This review describes the safety and tolerability of pertuzumab, a monoclonal antibody targeted at HER2 approved by the United States Food and Drug Administration (FDA) for use in the neoadjuvant and first line metastatic settings.EXPERT OPINION: The combination of trastuzumab, pertuzumab, and chemotherapy is approved in the neoadjuvant and first line metastatic settings and should be strongly considered by providers. Further studies are needed to look at side effect prevention, novel pertuzumab containing regimens, and re-treating patients with pertuzumab.INTRODUCTION: Approximately twenty to thirty percent of newly diagnosed breast cancers are human epidermal growth factor receptor 2 (HER2) positive. The use of trastuzumab, and more recently pertuzumab, has significantly improved the progression free survival (PFS) and overall survival (OS) in this patient population. However, pertuzumab has side effects that can impact treatment tolerability and quality of life.All authors: Gao J, Swain SMFiscal year: FY2016Digital Object Identifier: Date added to catalog: 2017-03-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 26982349 Available 26982349

AREAS COVERED: This review describes the safety and tolerability of pertuzumab, a monoclonal antibody targeted at HER2 approved by the United States Food and Drug Administration (FDA) for use in the neoadjuvant and first line metastatic settings.

EXPERT OPINION: The combination of trastuzumab, pertuzumab, and chemotherapy is approved in the neoadjuvant and first line metastatic settings and should be strongly considered by providers. Further studies are needed to look at side effect prevention, novel pertuzumab containing regimens, and re-treating patients with pertuzumab.

INTRODUCTION: Approximately twenty to thirty percent of newly diagnosed breast cancers are human epidermal growth factor receptor 2 (HER2) positive. The use of trastuzumab, and more recently pertuzumab, has significantly improved the progression free survival (PFS) and overall survival (OS) in this patient population. However, pertuzumab has side effects that can impact treatment tolerability and quality of life.

English

Powered by Koha